Jazz Pharmaceuticals plc - Form 4 Filing

This filing details transactions by Rick E. Winningham, a director at Jazz Pharmaceuticals plc. On May 22, 2026, Winningham acquired 3,415 ordinary shares through the exercise of a non-qualified stock option, with a conversion price of $138.08 per share. The option, granted on August 11, 2016, and fully vested by August 1, 2017, expired on August 10, 2026. Following this acquisition, Winningham disposed of 2,741 ordinary shares at a price of $241.57 per share. The post-transaction holdings reflect these changes, with 12,308 shares held after acquisition and 9,567 shares held after disposition. The filing also notes that the stock option was exercised and disposed of on the same day.